Clinical Trial

 

STRO-001-BM1

 

Sutro is currently advancing two wholly owned clinical-stage programs designed to provide patient benefit across multiple areas of unmet need.

STRO-001-BM1 is a CD74 Targeting antibody drug conjugate (ADC) for the potential treatment of multiple myeloma and NHL.

  • STRO-001-BCM1 is an ongoing first-in-human, phase 1, open-label, multicenter, dose escalation study evaluating the safety, tolerability and preliminary anti-tumor activity of STRO-001-BM1 in adults with B-cell malignancies (NHL and multiple myeloma).

STRO-001-BM1 is a novel homogeneous ADC using precisely positioned non-natural amino acids.

  • STRO-001-BM1 targets the tumor cell carrying two cytotoxins, these are non-cleavable maytansinoid linker-warheads (DAR=2) that are stable in circulation
  • The active warhead is internalized by the tumor cells, efficiently killing them while minimizing damage to surrounding healthy cells.

STRO–001-BM1 has received Orphan Drug designation for Multiple Myeloma patients.

For more information about this trial, visit www.clinicaltrials.gov

STRO-002-GM1

 

STRO-002-GM1 is a FolRa targeting ADC for the potential treatment of ovarian and endometrial cancer

  • STRO-002-GM1 is currently in an ongoing first-in-human, phase 1, open-label, multicenter, dose expansion study evaluating the safety, tolerability and preliminary anti-tumor activity of STRO-002-GM1 in adults with ovarian cancer.
  • STRO-002 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in August, 2021 for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of systemic therapy.

STRO-002-GM1 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids

  • STRO-002-GM1 targets the tumor cell carrying four cytotoxins, these are proprietary cleavable hemiasterlin linker-warheads (DAR=4) that are stable in circulation
  • The active warhead is internalized by the tumor cell, efficiently killing them in a manner that can stimulate the immune system, an effect called immunogenic cell death.[1]

For more information about this trial, visit www.clinicaltrials.gov

[1]Source: June 22, 2020 AACR 2020 Virtual Meeting II – Abstract 

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Contact Us

General Inquires: general@sutrobio.com
Business Inquires: busdev@sutrobio.com
Investor Relations Inquires: IR@sutrobio.com
Careers:
jobs@sutrobio.com